H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Intellia Therapeutics (NTLA) with a Buy rating and $30 price target Intellia is ...

Y Intercept Hong Kong Ltd acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the ...

Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...

If you purchased or acquired securities in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Details of the case: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for ...

Intellia Therapeutics, Inc. (NTLA) shares rallied 6.5% in the last trading session to close at $12.28. This move can be attributable to notable volume with a higher number of shares being traded than ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. Revenues were better than expected, with US$58m in revenue ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and ...

Intellia Therapeutics NTLA incurred a fourth-quarter 2024 loss of $1.24 per share (excluding one-time expenses of change in fair value of investments), which was narrower than the Zacks Consensus ...

Intellia Therapeutics reported better-than-expected results for the fourth quarter thanks to a boost in its collaboration ...